Altimmune, Inc. (ALT)
D
Pipeline Grade
Financial Position (from SEC Filings)
$97.6M
Cash & Equivalents
$20.9M
Quarterly Burn Rate
14 mo
Est. Cash Runway
$593M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-03-31 | Phase2 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06987513 | RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD... | PHASE2 | Active Not Recruiting | 100 |
| NCT07009860 | RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated ... | PHASE2 | Recruiting | 100 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.